Amneal Pharmaceuticals, Inc. (AMRX)

NMS – Real Time Price. Currency in USD

17.23

-0.09 (-0.52%)

At close: Jun 26, 2026, 4:00 PM EDT

16.85

-0.38 (-2.21%)

After-hours: Jun 26, 2026, 7:17 PM EDT

Stock details

Previous close: 17.475$
Day's range: 17.35 - 17.78$
52-week range: 7.67 - 17.78$
Volume: 708 460
Average volume: 2 039 539
Beta: 1.22
EPS (TTM): 0.39
PE ratio (TTM): 46.85
Forward P/E: 17.8
Market cap: 5 574 922 985
Shares outstanding: 319 022 775
Dividend yield: N/A
Next earnings date: 2026-08-12
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

About the company

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which in... read more

CEO: Chirag K. Patel
Country: United States
IPO Date
Employees: 8700
Fiscal Year End: January - December
Website: https://www.amneal.com

Revenue Breakdown

Affordable Medicines / 57.82%

AvKARE / 24.67%

Specialty / 17.51%

News

No Data

There are no news for this stock.

Chart: AMRX

Loading Chart...

Overall Score

4 / 1040%

Financial Strength

5.6

Profitability

6.4

Effectiveness

3.5

Growth

6.5

Forecast

5.8

Valuation

2.5

Dividend

Economic Moat

Octagon View

Strength & Weakness

Total debt $2.7B significantly exceeds cash reserves ($201.8M), raising financial stability concerns

Total current assets $1.8B exceed Total current liabilities $728.0M, highlighting excellent liquidity

Debt-to-equity ratio (67.5) far exceeds the industry average, reflecting over-leverage

Interest coverage ratio (3x) is sufficient but not particularly strong

Negative free cash flow -$42.6M limits the company's ability to reinvest or pay down debt

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	2.47	2.52	10
Quick ratio	1.59	1.78	8.0
Debt to Equity	N/A	-0.80	1.0
Debt to Assets	0.76	0.73	2.0
Interest coverage	2.68	-13.90	7.0
Weighted average score			5.6

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	2.21B	2.39B	2.79B	3.02B	3.05B
Gross Profit	796M	857M	1.02B	1.14B	1.18B
Operating Income	200M	263M	353M	423M	444M
Net Income	-130M	-84M	-117M	72M	122M
EBITDA	441M	492M	589M	647M	651M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	44.31	49.73	8.0
Operating margin %	19.77	0.39	9.0
Net margin %	8.62	-50.32	6.0
EBITDA margin %	25.75	-16.02	8.0
Cash flow margin %	-3.98	124.71	1.0
Weighted average score			6.4

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	1.45	-42.45	3.0
ROE	N/A	-63.95	1.0
ROIC	2.15	-2.18	5.0
ROCE	4.19	42.71	5.0
Weighted average score			3.5

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	4.98	-10.11	2.5
Next quarter	3.28	41.63	7.0
Current year	2.64	18.28	6.5
Next year	7.67	14.71	7.0
Weighted average score			5.8

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	-11.26	77.49	28.57	-148.86	5.5
Y/Y	3.9	410.5	28.57	-534.26	6.3
3y average	10.99	52.63	9.29	302.05	8.3
5y average	8.75	-250.78	8.56	154.98	5.8
Weighted average score					6.5

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	46.70	13.57	2.8
PEG (5yr expected)	N/A	0.41	1.0
P/S	1.85	-0.30	5.0
P/B	105.45	6.01	1.0
Weighted average score			2.5

DCF Model

DCF Model Period5 years

Discount rate8.5%

Perpetual growth rate3%

Revenue 5 year CAGR7.43%

FCF 5 year CAGR4

Fair value12.55$

Stock price17.25$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$12.55

UndervaluedStock priceOvervalued

$17.25

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Chirag K. Patel

Country

United States

IPO Date

Employees

8700

Fiscal Year End

January - December

Website

https://www.amneal.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

2.47

2.52

Quick ratio

1.59

1.78

8.0

Debt to Equity

N/A

-0.80

1.0

Debt to Assets

0.76

0.73

2.0

Interest coverage

2.68

-13.90

7.0

Weighted average score

5.6

METRIC

2022

2023

2024

2025

TTM

Total Revenue

2.21B

2.39B

2.79B

3.02B

3.05B

Gross Profit

796M

857M

1.02B

1.14B

1.18B

Operating Income

200M

263M

353M

423M

444M

Net Income

-130M

-84M

-117M

72M

122M

EBITDA

441M

492M

589M

647M

651M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

44.31

49.73

8.0

Operating margin %

19.77

0.39

9.0

Net margin %

8.62

-50.32

6.0

EBITDA margin %

25.75

-16.02

8.0

Cash flow margin %

-3.98

124.71

1.0

Weighted average score

6.4

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

1.45

-42.45

3.0

ROE

N/A

-63.95

1.0

ROIC

2.15

-2.18

5.0

ROCE

4.19

42.71

5.0

Weighted average score

3.5

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

4.98

-10.11

2.5

Next quarter

3.28

41.63

7.0

Current year

2.64

18.28

6.5

Next year

7.67

14.71

7.0

Weighted average score

5.8

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

-11.26

77.49

28.57

-148.86

5.5

Y/Y

3.9

410.5

28.57

-534.26

6.3

3y average

10.99

52.63

9.29

302.05

8.3

5y average

8.75

-250.78

8.56

154.98

5.8

Weighted average score

6.5

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

46.70

13.57

2.8

PEG (5yr expected)

N/A

0.41

1.0

P/S

1.85

-0.30

5.0

P/B

105.45

6.01

1.0

Weighted average score

2.5

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Amneal Pharmaceuticals, Inc. (AMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amneal Pharmaceuticals, Inc. (AMRX)

Stock details

About the company

Revenue Breakdown

News

Chart: AMRX

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$12.55

$17.25

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: AMRX

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$12.55

$17.25

Economic Moat